hERG block, QT liability and sudden cardiac death

Novartis Foundation Symposium

Volumn 266, Issue , 2005, Pages 118-131

  Brown, Arthur M ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b ChanTest Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ERG1 POTASSIUM CHANNEL; KCNH2 PROTEIN, HUMAN; POTASSIUM CHANNEL HERG; VOLTAGE GATED POTASSIUM CHANNEL;

ACTION POTENTIAL; ANIMAL; DRUG ANTAGONISM; HUMAN; LONG QT SYNDROME; METABOLISM; REVIEW; SUDDEN DEATH; TORSADE DES POINTES;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; DEATH, SUDDEN, CARDIAC; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; LONG QT SYNDROME; POTASSIUM CHANNELS, VOLTAGE-GATED; TORSADES DE POINTES;

EID: 23844440383     PISSN: 15282511     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (30)

1. Asmild M, Oswald N, Krzywkowski KM et al 2003 Upscaling and automation of electrophysiology: toward high throughput screening in ion channel drug discovery. Receptors Channels 9:49-58
2. Brown AM, Rampe D 2000 Drug-induced long QT syndrome: is hERG the root of all evil? Pharmaceutical News 7:15-20
3. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT 1995 A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 80:1-20
4. Drolet B, Simard C, Roden DM 2004 Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation 109:26-29
5. Ficker E, Obejero-Paz CA, Zhao S, Brown AM 2002 The binding site for channel blockers that rescue misprocessed LQT2 hERG mutations. J Biol Chem 277:4989-4998
6. Ficker E, Dennis AT, Wang L, Brown AM 2003 Role of the cytosolic chaperones Hsp70 and Hsp90 in maturation of the cardiac potassium channel hERG. Circ Res 92:e87-e100
7. Ficker E, Kuryshev Y, Dennis AT et al 2004 Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol 66:33-44
8. Kr Blockade. 2003 Barnett International QT Prolongation Conference, November, Philadelphia, USA
9. ICH Expert Working Group 2002 Safety pharmacology studies for assessing the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals
10. Imredy JP, Irving WD, Clouse HK, Salata JJ 2004 Electrophysiological and pharmacological characterization of a cell line stably expressing hKCNQ1 and hKCNE1 potassium channels. 2004 Biophysical Society Annual Meeting (abstr)
11. Jervell A, Lange-Nielsen F 1957 Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J 54:59-68
12. Kang J, Chen XL, Wang H et al 2004 Cardiac ion channel effects of tolterodine. J Pharmacol Exp Ther 308:935-940
13. Kirsch GE, Trepakova ES, Brimecombe JC et al 2004 Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J Pharmacol Toxicol Methods, accepted 50:93-101
14. Lacerda AE, Kramer J, Shen K-Z, Thomas D, Brown AM 2001 Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs. Eur Heart J Suppl 3:K23-K30
15. + channel by the gastrointestinal prokinetic agent cisapride. Am J Physiol 273:H2534-H2538
16. c interval: impact on defining drug effect and low-frequency cardiac event. Am J Cardiol 72:26B-31B
17. Ohnishi K, Yoshida H, Shigeno K et al 2000 Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 133:881-885
18. Rampe D, Roy ML, Dennis A, Brown AM 1997 A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel hERG. FEBS Lett 417:28-32
19. Redfern WS, Carlsson L, Davis AS et al 2003 Relationships between non-clinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:32-45
20. Roden DM 1993 Current status of class III antiarrhythmic drug therapy. Am J Cardiol 72:44B-49B
21. Romano C, Gemme G, Pongiglione R 1963 Aritmie cardiache rare dell'età pediatrica. Clin Pediatr 45:656-683
22. Roy M-L, Dumaine R, Brown AM 1996 HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation 94:817-823
23. Kr potassium channel. Cell 81:299-307
24. Schroeder K, Neagle B, Trezise DJ, Worley J 2003 Ionworks™ HT: a new high throughput electrophysiology measurement platform. J Biomol Screen 8:50-64
25. Tang W, Kang J, Wu X et al 2001 Development and evaluation of high throughput functional assay methods for HERG potassium channel. J Biomol Screen 6:325-331
26. Unnikrishnan D, Dutcher JP, Varshneya N et al 2001 Torsade de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 97:1514-1516
27. Ward OC 1964 A new familial cardiac syndrome in children. J Ir Med Assoc 54:103-106
28. Wible BA, Hawryluk P, Ficker E, Brown AM 2003 HERG-Lite™, a novel high throughput hERG cardiac safety test. 2003 Society for Biomolecular Screening Annual Meeting (abstr)
29. Woosley RL, Chen Y, Froiman JP, Gillis RA 1993 Mechanism of the cardiotoxic actions of terfenadine. J Am Med Assoc 269:1532-1536
30. Zhang S, Zhou Z, Gong Q, Makielski JC, January CT 1999 Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 89:989-998